Samsung Biologics shareholders are experiencing recent volatility as the company prepares a major stock offering to fund factory expansion. The broader biotech industry is going through a correction as investor views shift, reported Dailian.
The company's share price peaked in July but has declined as market sentiment moved toward profitable companies instead of high-growth companies. Biotech stock offerings become expensive when stock prices drop. Samsung Biologics makes biologic drugs for global pharmaceutical companies on a contract manufacturing basis.
The company faces constraints on how much it can produce. Samsung Biologics needs new manufacturing capacity to keep growing its contract manufacturing business for global pharmaceutical companies.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |